

Index to Volume 146

Author Index, 1974

- Aboul-Encin, Hassan Y.**
Psilocybin: A Pharmacological Profile, 91
- Barringer, William C.**
Minocycline Hydrochloride and Its Relationship to Other Tetracycline Antibiotics, 179
- Hussar, Daniel A.**
New Drugs of 1973, 37
- Kourounakis, P.**
Nonspecific Resistance to Drugs, 22
- Kratz, Allen M.**
Patient Dosage Instructions: A Guide for Pharmacists (BR), 29
Pharmaceutical Services to Nursing Homes and Related Health Facilities: Undergraduate and Continuing Education Programs, 59
- McNeil, Henry S.**
Prices and Values, 133
- Nash, Robert A.**
See *Barringer, William C.*
- Orzechowski, Raymond F.**
Inflammatory Disorders. II. Pharmacology of Anti-Inflammatory Agents (Study Guide), 150
- Osol, Arthur**
Combination Chemotherapy in Advanced Hodgkin's Disease (AR), 30
Hyperpyrexia from Phenothiazine-Anticholinergic Drug Combination (AR), 63
Penicillamine in the Treatment of Rheumatoid Arthritis (AR), 127
Use of Pharmacokinetic Principles in Therapy (AR), 29
- Parsons, William H.**
The United States Dispensatory (BR), 162
- Schneller, George H.**
A Perspective on Drug Reaction Reporting, 70
Pharma-phantasy, 192
- Schultz, Walter**
See *Barringer, William C.*
- Sieger, George M.**
See *Barringer, William C.*
- Snader, Thomas C.**
Inflammatory Disorders. I. Classification, Anatomy, and Pathophysiology (Study Guide), 113
Inflammatory Disorders. III. Clinical Management (Study Guide), 169
- Swintosky, Joseph V.**
Pharmaceutical Education in the United States of America—Professional and Graduate, 75
- Tice, Linwood F.**
Inflation (E), 167
Mandatory Continuing Education (E), 3
Our New Drug Review (E), 35
Population Control—A Must (E), 131
The Pharmacist and Drug Product Selection (E), 67
USP-NF Consolidation (E), 99
- Weaver, Lawrence C.**
Continuing Education, an Opportunity, 5
- Weiss, Peter J.**
Improving Drug Quality through Certification Experience, 86
- Young, Donald W.**
Security for the Community Pharmacy, 15
- Zink, Gilbert L.**
Principles of Immunity. I. Antigens, Antibody Production, and Immediate Hypersensitivity, 101
Principles of Immunity. II. Cellular Immunology and Immunogenetics, 138

Note: The abbreviations used herein are as follow—(AR) Article Review; (BN) Book Notice; (BR) Book Review; (E) Editorial.

Subject Index, 1974

- Aarane, 44
 Aberel, 56
 Acetaminophen, 171, 175
 ACTH, 155, 176
 Adrenal corticosteroids, 173
 Adverse reactions, 70, 86
 Alka Seltzer, 170
 Allopurinol, 157, 176
 Alupent, 45
 Amantadine, 57
 Aminoquinolones, 171
 Anacin, 170
 Analgesics, 170
 Ancef, 37
 Anesthetics, local, 53
 Antiasthmatics, 44
 Antibodies, 105
 Antigens, 101
 Antigens, histocompatible, 146
 Antihypertensives, 42
 Anti-infectives, 37
 Anti-inflammatory agents, pharmacology, 150
 Antimalarial drugs, 175
 Antineoplastics, 46
 Anturane, 159
 APC, 170
 Appetite suppressants, 49
 Aralen, 153
 Artane, 57
 Arthritis, rheumatoid, 113, 152, 169
 Arthritis, therapeutic agents, 159
 Ascriptin, 170
 Aspergum, 170
 Aspirin, 150, 170, 175, 178
 Aspirin-containing products, OTC, 170
 Australian Pharmaceutical Formulary and Handbook, 11th ed (BN), 163

 Benemid, 158
 Benisone, 56
 Betamethasone, 56

 Bioavailability, 89
 Blastogen, 138
 Blenoxane, 47
 Bleomycin, 47
 Brain and Hypertension, The, 10
 Bromo-Seltzer, 170
 Bufferin, 170
 Bufferin, Arthritis Strength, 170
 Bufotenine, 91
 Bupivacaine, 53
 Butazolidin, 152

 Calusterone, 46
 Cefazolin, 37
 Chemist's Guide to Regulatory Drug Analysis, A (BN), 126
 Chloroquine, 153, 171
 Cholestyramine, 57
 Clortermine, 51
 Clinical orientation in pharmaceuticals education, 81
 Colchicine, 157, 176
 Collagenase ABC, 52
 Combination Chemotherapy in Advanced Hodgkin's Disease (AR), 30
 Commencement Address 1974, Philadelphia College of Pharmacy and Science, 133
 Community pharmacy, 15
 Continuing education, 3, 83
 Continuing Education, an Opportunity, 5
 Contraceptive, oral, 55
 Corticosteroids, 175
 Corticotropin, 155, 173
 Cromolyn sodium, 44
 Cuemid, 58
 Cyclophosphamide, 174
 Cytotoxic drugs, 174
 Cytotoxin, 139

 Debridging agent, topical, 52

 Degenerative joint disease, 174
 Diazepam, 175
 Diazoxide, 42
 Diethylstilbestrol, 57
 Dinoprost tromethamine, 58
 Dopar, 57
 Drug Interactions and Their Mechanisms (BN), 126
 Drug product selection, 67
 Drug reaction reporting, 70

 Epsilon-aminocaproic acid, 175
 Excedrin, 170
 Excedrin P.M., 170

 Fenfluramine, 49
 Flucanide, 56
 Fluorbat, 56

 Gelusil, 170
 Glucocorticoids, 155
 Gold compounds, 153, 154, 171
 Gout, 113, 157, 175
 Graduate pharmaceutical education, 84

 Histocompatible antigens, 146
 Historical Medical Classics Involving New Drugs (BN), 126
 Homeostasis, 22
 Hydrocortisone, 155
 Hydroxychloroquine, 153, 171
 Hyperpyrexia from Phenothiazine-Anticholinergic Drug Combination (AR), 63
 Hypersensitivity, immediate, 107
 Hyperstat, 42
 Hypertension, 10

Note: The abbreviations used herein are as follow—(AR) Article Review; (BN) Book Notice; (BR) Book Review; (E) Editorial.

- Iletin, 56
 Imipramine, 57
 Imipramine pamoate, 56
 Immunity, acquired, 106
 Immunity, cellular, 138
 Immunity, humoral, 103
 Immunogenetics, 145
 Immunogens, 101
 Immunoglobulins, 103
 Immunological deficiencies, 147
 Immunological enhancement, 143
 Immunological tolerance, 142
 Immunology and cancer control, 143
 Improving Drug Quality through Certification Experience, 86
 Indene derivatives, 171
 Inderal, 57
 Index Nominum 1973/74 (BN), 126
 Indocin, 152, 171
 Indomethacin, 152, 171, 175, 176
 Inflammatory Disorders. I. Classification, Anatomy, and Pathophysiology (Study Guide), 113
 Inflammatory Disorders. II. Pharmacology of Anti-Inflammatory Agents (Study Guide), 150
 Inflammatory Disorders. III. Clinical Management (Study Guide), 169
 Inflammatory disorders, therapeutic agents, 159
 Inflation (E), 167
 Insulin, 56
 Intal, 44
 Interferon, 138

 Kefzol, 37

 Larodopa, 57
 Levodopa, 57
 Lidex, 56
 Loestrin 1.5/30, 55
 LSD-25, 91

 Mandatory Continuing Education (E), 3
 Marcaine, 53
 Mazindol, 51
 Measurin, 170
 Meprobamate, 175
 Mescaline, 91

 Mestonon, 55
 Metaprel, 45
 Metaproterenol, 45
 Methosarb, 46
 Micronor, 55
 Migration-inhibiting factor (MIF), 138
 Minocin, 179
 Minocin Intravenous, 190
 Minocycline Hydrochloride and Its Relationship to Other Tetracycline Antibiotics, 179

 Nalidixic acid, 42
 NegGram, 42
 New Drugs of 1973, 37
 NF, 99
 Nonspecific Resistance to Drugs, 22
 Norethindrone, 55
 Nor-QD, 55

 Ophthalmic ointments, sterility, 88
 Oral contraceptive, 55
 Osteoarthritis, 113
 Our New Drug Review (E), 35
 Oxyphenbutazone, 152, 171, 176

 Parity tolerance, 142
 Patient Dosage Instructions: A Guide for Pharmacists (BR), 29
 Penicillamine, 172
 Penicillamine in the Treatment of Rheumatoid Arthritis (AR), 127
 Percogesic, 170
 Persistin, 170
 Perspective on Drug Reaction Reporting, A, 70
 Pharmaceutical Education in the United States of America—Professional and Graduate, 75
 Pharmaceutical education, graduate, 84
 Pharmaceutical Services to Nursing Homes and Related Health Facilities: Undergraduate and Continuing Education Programs, 59
 Pharmacist and Drug Product Selection, The (E), 67
 Pharma-phantasy, 192
 Phenacetin, 171

 Phenylbutazone, 152, 171, 175, 176
 Piperacetazine, 56
 Plaquenil, 153
 Polycillin-PRB, 41
 Pondimin, 49
 Population Control—A Must (E), 131
 Presamine, 57
 Prices and Values, 133
 Principles of Immunity. I. Antigens, Antibody Production, and Immediate Hypersensitivity, 101
 Principles of Immunity. II. Cellular Immunology and Immunogenetics, 138
 Probenecid, 158, 177
 Professional pharmacy degrees, 79
 Propranolol, 57
 Prostin F2 Alpha, 58
 Psilocin, 91
 Psilocybin: A Pharmacological Profile, 91
 Psychosocial Pharmacy: The Synthetic Society (BN), 126
 Purified protein derivative (PPD), 139
 Pyrazole derivatives, 159
 Pyrazolone derivatives, 171
 Pyridostigmine bromide, 55

 Quality control on new packaging, 87
 Questran, 57
 Quide, 56

 Regonol, 55
 Rejection, graft, 141
 Rejection, transplant, 140
 Retin-A, 56
 Rheumatism, 113
 Rumalon, 175

 Sacred Narcotic Plants of the New World Indians (BN), 126
 Salicylates, 150, 159, 170
 Sanorex, 51
 Security for the Community Pharmacy, 15
 Silvadene, 40
 Silver sulfadiazine, 40
 Sodium salicylate, 150
 Stanback, 170
 Steroids, 176
 Steroids, anti-inflammatory, potencies, 156

- | | | |
|-------------------------------|-----------------------------|------------------------------|
| Sulfinpyrazone, 159, 177 | Trigesic, 170 | USP-NF Consolidation (E), 99 |
| Symmetrel, 57 | Trihexyphenidyl, 57 | |
| | Trimethoprim, 38 | |
| | Tumor specific | |
| | transplantation antigens | |
| | (TSTA's), 143 | |
| Tandearil, 152 | | Valisone, 56 |
| T cells, 138 | | Vancocin, 42 |
| Tofranil, 57 | | Vancomycin, 42 |
| Tofranil-PM, 56 | | Vanquish, 170 |
| Tolerance, fetal, 142 | United States Dispensatory, | Vectrin, 179 |
| Tolerance, immunological, 142 | The (BR), 162 | Voranil, 51 |
| Tolerance, parity, 142 | Uricosuric agents, 158 | |
| Topsyn, 56 | Use of Pharmacokinetic | |
| Tretinoin, 56 | Principles in Therapy | Zoranc, 55 |
| | (AR), 29 | Zyloprim, 157 |

